ELI LILLY & Co (LLY) KPIs and segments
Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Eli Lilly · năm tài chính kết thúc December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Eli Lilly: 92 chỉ số vận hành, trong đó có Consolidated revenue, Worldwide revenue growth YoY và U.S. revenue growth YoY, lấy từ 157 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product revenue($M) | 22,650 | 21,403 | 18,453 | 18,300 | 16,331 | 14,726 | 11,601 | 12,025 | 10,572 | 10,355 | 7,797 | 8,290 | |
Cardiometabolic Health($M)2 | 19,764 | 18,353 | 15,760 | 13,178 | 11,343 | 9,208 | 7,407 | 7,515 | 5,493 | ||||
United States($M) | 12,376 | 11,742 | 9,924 | 10,057 | 8,867 | 8,363 | 6,577 | 6,527 | 5,517 | 5,716 | 4,090 | 4,465 | |
Outside U.S.($M) | 7,388 | 6,611 | 5,836 | 4,435 | 4,311 | 2,980 | 2,631 | 2,579 | 1,890 | 1,799 | 1,403 | 1,282 | |
Mounjaro($M)2 | 10,723 | 9,943 | 8,662 | 6,515 | 5,199 | 3,842 | 3,113 | 3,091 | 1,807 | ||||
Outside U.S.($M) | 5,725 | 5,152 | 4,430 | 3,267 | 2,965 | 1,897 | 1,186 | 899 | 728 | 677 | 286 | 101 | |
United States($M) | 4,998 | 4,791 | 4,232 | 4,143 | 3,550 | 3,302 | 2,656 | 2,631 | 2,385 | 2,414 | 1,520 | 2,105 | |
Zepbound($M)2 | 5,352 | 4,928 | 4,160 | 3,588 | 3,381 | 2,312 | 1,258 | 1,243 | 517 | ||||
United States($M) | 5,267 | 4,873 | 4,134 | 4,230 | 3,568 | 3,380 | 2,305 | 1,908 | 1,258 | 1,243 | 517 | 176 | |
Outside U.S.($M) | 86 | 55 | 26 | 30 | 20 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | |
Oncology($M)2 | 2,600 | 2,570 | 2,268 | 2,408 | 2,414 | 1,948 | 2,232 | 2,159 | 1,810 | ||||
United States($M) | 1,518 | 1,473 | 1,228 | 1,512 | 1,375 | 1,419 | 1,046 | 1,468 | 1,294 | 1,275 | 998 | 1,107 | |
Outside U.S.($M) | 1,082 | 1,097 | 1,040 | 1,095 | 1,033 | 994 | 902 | 1,084 | 938 | 884 | 812 | 777 | |
Collaboration and other revenue($M) | 1,747 | 1,571 | 1,346 | 992 | 1,270 | 832 | 1,127 | 1,508 | 868 | 948 | 972 | 1,064 | |
Jardiance($M)2 | 1,578 | 1,232 | 1,114 | 769 | 959 | 690 | 1,014 | 1,199 | 686 | 770 | 687 | 798 | |
Outside U.S.($M) | 796 | 615 | 602 | 302 | 535 | 308 | 705 | 734 | 351 | 341 | 318 | 329 | |
United States($M) | 781 | 616 | 512 | 466 | 424 | 382 | 310 | 465 | 336 | 429 | 368 | 469 | |
Verzenio($M)2 | 1,511 | 1,474 | 1,302 | 1,470 | 1,489 | 1,159 | 1,369 | 1,332 | 1,050 | ||||
United States($M) | 897 | 845 | 706 | 997 | 880 | 929 | 658 | 1,043 | 879 | 861 | 638 | 775 | |
Outside U.S.($M) | 614 | 629 | 596 | 608 | 590 | 560 | 501 | 513 | 490 | 471 | 412 | 370 | |
Immunology($M)2 | 1,435 | 1,417 | 1,203 | 1,362 | 1,256 | 1,088 | 1,186 | 1,082 | 834 | ||||
United States($M) | 801 | 790 | 619 | 912 | 773 | 701 | 578 | 767 | 694 | 600 | 397 | 605 | |
Outside U.S.($M) | 634 | 627 | 584 | 629 | 589 | 555 | 510 | 524 | 492 | 483 | 437 | 499 | |
Other cardiometabolic health($M)2 | 1,207 | 1,031 | 905 | 1,064 | 980 | 945 | 1,049 | 1,165 | 1,026 | ||||
United States($M) | 729 | 554 | 446 | 524 | 618 | 556 | 535 | 723 | 603 | 754 | 602 | 2,607 | |
Outside U.S.($M) | 479 | 477 | 460 | 492 | 446 | 425 | 410 | 496 | 446 | 412 | 424 | 1,454 | |
Other oncology($M)2 | 1,089 | 1,096 | 966 | 937 | 924 | 789 | 863 | 827 | 760 | ||||
United States($M) | 621 | 628 | 522 | 515 | 495 | 490 | 388 | 426 | 416 | 414 | 360 | 1,034 | |
Outside U.S.($M) | 468 | 468 | 444 | 488 | 443 | 434 | 400 | 572 | 447 | 413 | 400 | 1,152 | |
Trulicity($M)2 | 904 | 1,219 | 919 | 1,052 | 1,092 | 1,095 | 1,301 | 1,246 | 1,456 | ||||
United States($M) | 601 | 908 | 600 | 693 | 707 | 744 | 771 | 800 | 935 | 877 | 1,082 | 1,255 | |
Outside U.S.($M) | 302 | 312 | 318 | 344 | 345 | 348 | 325 | 451 | 366 | 369 | 374 | 413 | |
Taltz($M)2 | 856 | 856 | 733 | 902 | 848 | 762 | 880 | 825 | 604 | ||||
United States($M) | 539 | 539 | 417 | 724 | 583 | 549 | 477 | 665 | 600 | 539 | 347 | 538 | |
Outside U.S.($M) | 316 | 317 | 315 | 328 | 318 | 299 | 285 | 286 | 279 | 285 | 257 | 247 | |
Other immunology($M)2 | 579 | 561 | 470 | 461 | 408 | 326 | 306 | 258 | 230 | ||||
Outside U.S.($M) | 318 | 310 | 269 | 302 | 271 | 256 | 225 | 238 | 212 | 197 | 180 | 773 | |
United States($M) | 262 | 251 | 202 | 187 | 190 | 152 | 102 | 102 | 93.8 | 60.4 | 50.1 | 226 | |
Neuroscience($M)2 | 444 | 429 | 382 | 316 | 344 | 272 | 352 | 340 | 389 | ||||
United States($M) | 384 | 325 | 293 | 320 | 240 | 248 | 189 | 224 | 201 | 192 | 163 | 183 | |
Outside U.S.($M) | 59 | 104 | 89 | 139 | 76 | 96 | 83 | 170 | 151 | 148 | 226 | 180 | |
Other($M)2 | 154 | 205 | 187 | 337 | 202 | 213 | 263 | 208 | 242 | ||||
Outside U.S.($M) | 97 | 122 | 130 | 114 | 292 | 119 | 113 | 145 | 156 | 155 | 196 | 161 | |
United States($M) | 57 | 84 | 56 | 77 | 45 | 83 | 100 | 46 | 107 | 52.2 | 45.7 | 95.2 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)19 | |||||||||||||
United States($M) | 15,136 | 14,413 | 12,119 | 12,877 | 11,300 | 10,814 | 8,489 | 9,032 | 7,814 | 7,835 | 5,694 | 6,455 | |
Outside U.S.($M) | 9,261 | 8,561 | 7,680 | 6,415 | 6,301 | 4,743 | 4,239 | 4,501 | 3,626 | 3,468 | 3,074 | 2,898 | |
Europe($M) | 4,459 | 4,115 | 3,646 | 3,097 | 3,498 | 2,574 | 2,389 | 2,448 | 1,628 | 1,404 | 1,441 | 1,338 | |
Rest of world($M) | 3,206 | 2,877 | 2,771 | 2,190 | 1,688 | 1,182 | 997 | 1,064 | 1,108 | 1,206 | 893 | ||
China($M) | 947 | 941 | 693 | 474 | 560 | 466 | 451 | 429 | 460 | 395 | 376 | 377 | |
Japan($M) | 648 | 628 | 571 | 654 | 555 | 521 | 402 | 559 | 429 | 463 | 364 | 439 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Consolidated revenue ($M)($M) | 22,974 | 19,799 | 19,292 | 17,601 | 15,558 | 12,729 | 13,533 | 11,439 | 11,303 | 8,768 | 9,353 | ||
Worldwide revenue growth YoY (%)(%)3 | 48.0% | 56.0% | 43.0% | 54.0% | 38.0% | 45.0% | 45.0% | 20.0% | 36.0% | 26.0% | 28.0% | ||
Worldwide volume growth impact YoY (%)(%) | 60.0% | 65.0% | 46.0% | 62.0% | 42.0% | 53.0% | 48.0% | 15.0% | 27.0% | 16.0% | |||
Worldwide realized price impact YoY (%)(%) | -13.0% | -13.0% | -5.0% | -10.0% | -6.0% | -6.0% | -4.0% | 6.0% | 10.0% | 10.0% | |||
Worldwide foreign exchange impact YoY (%)(%) | 1.0% | 4.0% | 4.0% | 2.0% | 1.0% | -2.0% | -1.0% | -1.0% | |||||
U.S. revenue growth YoY (%)(%)2 | 33.0% | 43.0% | 43.0% | 45.0% | 38.0% | 49.0% | 40.0% | 46.0% | 42.0% | 28.0% | 39.0% | ||
U.S. volume growth impact YoY (%)(%) | 37.0% | 49.0% | 50.0% | 60.0% | 46.0% | 57.0% | 45.0% | 35.0% | 27.0% | 12.0% | 12.0% | ||
U.S. realized price impact YoY (%)(%) | -3.0% | -7.0% | -7.0% | -15.0% | -8.0% | -7.0% | -5.0% | 11.0% | 15.0% | 16.0% | -3.0% | ||
Outside U.S. revenue growth YoY (%)(%)3 | 80.0% | 81.0% | 43.0% | 74.0% | 37.0% | 38.0% | 55.0% | -12.0% | 25.0% | 22.0% | 10.0% | ||
Outside U.S. volume growth impact YoY (%)(%) | 113.0% | 95.0% | 38.0% | 66.0% | 35.0% | 46.0% | 56.0% | -10.0% | 27.0% | 23.0% | 10.0% | ||
Outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K](%) | -36.0% | -25.0% | 3.0% | -1.0% | -3.0% | -1.0% | -3.0% | ||||||
Outside U.S. foreign exchange impact YoY (%)(%) | 4.0% | 11.0% | 4.0% | 6.0% | 3.0% | -5.0% | -1.0% | -3.0% | 3.0% | ||||
Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M)($M)1 | 9,943 | 8,662 | 7,409 | 6,515 | 5,199 | 3,842 | 3,530 | 3,113 | 3,091 | 1,807 | 2,206 | ||
Mounjaro — Worldwide revenue growth YoY (%)(%) | 91.0% | 125.0% | 110.0% | 109.0% | 68.0% | 113.0% | 60.0% | 132.4% | 64.0% | 32.0% | |||
Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M)($M)1 | 4,928 | 4,160 | 4,261 | 3,588 | 3,381 | 2,312 | 1,907 | 1,258 | 1,243 | 517 | 176 | ||
Zepbound — Worldwide revenue growth YoY (%)(%) | 46.0% | 80.0% | 123.0% | 185.0% | 172.0% | ||||||||
Trulicity (dulaglutide) — U.S. revenue ($M)($M)1 | 908 | 600 | 693 | 707 | 744 | 771 | 800 | 935 | 877 | 1,082 | 1,255 | ||
Trulicity — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%) | 12.0% | -16.0% | 366.0% | 368.9% | 374.4% | -25.0% | -22.0% | -31.0% | -26.0% | -14.0% | |||
Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M)($M)2 | 1,232 | 1,114 | 769 | 959 | 690 | 1,014 | 1,199 | 686 | 770 | 687 | 798 | ||
Jardiance commercial milestone collaboration revenue ($M)($M) | 250 | 250 | 0 | 200 | 0 | 370 | |||||||
Jardiance — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%) | 79.0% | 10.0% | 350.5% | 340.7% | 318.3% | 50.0% | -2.0% | 15.0% | 19.0% | 30.0% | |||
Verzenio (abemaciclib) — Worldwide revenue ($M)($M)1 | 1,474 | 1,302 | 1,604 | 1,470 | 1,489 | 1,159 | 1,555 | 1,369 | 1,332 | 1,050 | 1,145 | ||
Verzenio — Worldwide revenue growth YoY (%)(%) | -1.0% | 12.0% | 3.0% | 7.0% | 12.0% | 10.0% | 36.0% | 32.0% | 44.0% | 40.0% | 42.0% | ||
Taltz (ixekizumab) — U.S. revenue ($M)($M)1 | 539 | 417 | 724 | 583 | 549 | 477 | 665 | 600 | 539 | 347 | 538 | ||
Taltz — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%) | 1.0% | -4.0% | 279.3% | 285.3% | 257.0% | 21.0% | 18.0% | 17.0% | 15.0% | 11.0% | |||
Non-major products combined ('Other products' in MD&A) — Worldwide revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)3 | 3,322 | 2,910 | 6,017 | 6,027 | 5,488 | 5,416 | 1,536 | 682 | 644 | 610 | 698 | ||
Non-major products combined — U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M) | 1,842 | 1,517 | 3,507 | 3,301 | 3,204 | 2,871 | 492 | 326 | 279 | 208 | 203 | ||
Non-major products combined — Outside U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M) | 1,481 | 1,393 | 2,510 | 2,726 | 2,285 | 2,545 | 1,044 | 357 | 364 | 402 | 496 | ||
Non-major products combined — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY 10-K](%) | 16.0% | 14.0% | 6.0% | -3.0% | 196.2% | 29.0% | 2.0% | 1.0% | |||||
Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 620 | 535 | 632 | 539 | 367 | ||||||||
Humalog (insulin lispro) — Worldwide revenue YoY (%) [legacy](%) | 69.0% | 35.0% | 43.0% | 17.0% | -33.0% | ||||||||
Humulin (human insulin) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 280 | 207 | 224 | 206 | 188 | ||||||||
Humulin (human insulin) — Worldwide revenue YoY (%) [legacy](%) | 61.2% | 9.0% | -18.0% | ||||||||||
Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 177 | 162 | 181 | 158 | 185 | ||||||||
Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy](%) | -10.0% | 17.0% | -25.0% | ||||||||||
Cyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 259 | 236 | 249 | 230 | 254 | ||||||||
Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy](%) | 5.0% | -4.0% | -3.0% | -9.0% | |||||||||
Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 175 | 152 | 156 | 145 | 150 | ||||||||
Erbitux (cetuximab) — Worldwide revenue YoY (%) [legacy](%) | -1.0% | -4.0% | 11.0% | ||||||||||
Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 250 | 203 | 192 | 226 | 186 | ||||||||
Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy](%) | 20.0% | 13.0% | 46.0% | 6.0% | |||||||||
Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 262 | 251 | 228 | 217 | 243 | ||||||||
Olumiant (baricitinib) — Worldwide revenue YoY (%) [legacy](%) | 8.0% | 4.0% | -5.0% | 18.0% | |||||||||
Tyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 136 | 150 | 123 | 117 | 114 | ||||||||
Tyvyt (sintilimab) — Worldwide revenue YoY (%) [legacy](%) | 30.0% | 19.0% | 91.0% | 98.0% | |||||||||
Alimta (pemetrexed) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 44.9 | ||||||||||||
Alimta (pemetrexed) — Worldwide revenue YoY (%) [legacy](%) | -81.0% | ||||||||||||
Forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 118 | 69.9 | 61.3 | 116 | |||||||||
Forteo (teriparatide) — Worldwide revenue YoY (%) [legacy](%) | -19.0% | -53.0% | -50.0% | ||||||||||
Cialis (tadalafil) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 91.5 | 87.7 | 139 | 78.8 | |||||||||
Cialis (tadalafil) — Worldwide revenue YoY (%) [legacy](%) | 5.0% | -24.0% | 39.0% | ||||||||||
Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 8.80 | 31.7 | 43.8 | ||||||||||
Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy](%) | -98.0% | ||||||||||||
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)1 | 0 | ||||||||||||
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy](%) | -100.0% | ||||||||||||
Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy](%) | 14.0% | ||||||||||||
Consolidated sales rebates and discounts liability ($M)($M) | 21,122 | 17,547 | 17,382 | 17,620 | 14,537 | 11,550 | 11,539 | 12,430 | 12,447 | 9,430 | 11,689 | ||
Total research and development expense ($M)($M)2 | 3,819 | 3,510 | 3,802 | 3,466 | 3,336 | 2,734 | 3,023 | 2,734 | 2,711 | 2,523 | 2,562 | ||
Early-stage research and discovery expense ($M)($M) | 1,450 | 1,266 | 1,485 | 1,250 | 1,156 | 990 | 1,044 | 995 | 1,025 | 852 | |||
Late-stage clinical development expense ($M)($M) | 2,368 | 2,244 | 2,316 | 2,216 | 2,180 | 1,744 | 1,979 | 1,739 | 1,686 | 1,671 | |||
Acquired in-process research and development (IPR&D) charges ($M)($M)1 | 2,776 | 584 | 529 | 656 | 154 | 1,572 | 189 | 2,826 | 154 | 111 | 620 | ||
Cash paid for IPR&D and development milestones ($M)($M) | 3,282 | 204 | 424 | 720 | 107 | 1,757 | 251 | 2,820 | 178 | 96.5 | 580 | ||
Asset impairment, restructuring and other special charges ($M)($M) | 703 | 279 | 84.1 | 365 | 0 | 35 | 344 | 81.6 | 435 | 0 | 68 | ||
GAAP gross margin ($M)($M)1 | 19,706 | 16,222 | 15,920 | 14,593 | 13,110 | 10,504 | 11,129 | 9,268 | 9,133 | 7,095 | 7,565 | ||
GAAP gross margin (% of revenue)(%) | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | ||
Non-GAAP gross margin ($M)($M)2 | 19,831 | 16,350 | 16,044 | 14,712 | 13,232 | 10,627 | 11,265 | 9,408 | 9,272 | 7,234 | 7,694 | ||
Non-GAAP gross margin (% of revenue)(%) | 86.3% | 82.6% | 83.2% | 83.6% | 85.0% | 83.5% | 83.2% | 82.2% | 82.0% | 82.5% | 82.3% | ||
Amortization of intangible assets in cost of sales ($M)($M) | 125 | 128 | 124 | 119 | 122 | 123 | 136 | 139 | 139 | 139 | 129 | ||
Non-GAAP net income ($M)($M)1 | 7,493 | 7,663 | 6,771 | 6,312 | 5,679 | 3,004 | 4,806 | 1,065 | 3,541 | 2,335 | 2,249 | ||
Non-GAAP diluted earnings per share ($)($) | 8.38 | 8.55 | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | ||
GAAP effective tax rate (%)(%)1 | 23.3% | 16.4% | 19.7% | 22.8% | 16.5% | 20.2% | 12.5% | 38.9% | 15.6% | 11.6% | 12.7% | ||
Non-GAAP effective tax rate (%)(%) | 22.2% | 16.5% | 19.7% | 17.7% | 16.5% | 20.2% | 13.2% | 37.6% | 16.5% | 11.9% | 13.1% | ||
Total inventories, net ($M)($M)2 | 16,793 | 14,529 | 13,744 | 12,180 | 11,014 | 9,311 | 7,589 | 7,460 | 6,482 | 6,102 | 5,773 | ||
Total inventories, gross (FIFO cost before LIFO reserve, $M)($M)3 | 16,755 | 14,492 | 13,701 | 12,219 | 11,015 | 9,282 | 7,526 | 7,386 | 6,394 | 6,005 | 5,670 | ||
Finished goods inventory ($M)($M) | 2,630 | 2,273 | 1,931 | 1,547 | 1,355 | 1,298 | 1,221 | 1,114 | 811 | 700 | 792 | ||
Work in process (WIP) inventory ($M)($M) | 9,997 | 8,456 | 8,183 | 7,275 | 6,509 | 5,296 | 3,979 | 4,035 | 3,706 | 3,612 | 3,249 | ||
Raw materials and supplies inventory ($M)($M) | 4,128 | 3,763 | 3,587 | 3,397 | 3,151 | 2,687 | 2,326 | 2,237 | 1,876 | 1,694 | 1,630 | ||
LIFO inventory valuation reserve ($M)($M) | -38 | -37 | -43 | 38.4 | 1.40 | -29.3 | -63 | -73.4 | -87.7 | -96.5 | -102 | ||
Property and equipment, net ($M)($M)1 | 29,286 | 26,540 | 24,675 | 22,316 | 20,530 | 18,474 | 17,102 | 16,172 | 14,829 | 13,624 | 12,914 | ||
Accumulated depreciation ($M)($M) | 13,103 | 12,560 | 12,411 | 12,554 | 12,147 | 11,789 | 11,816 | 11,428 | 11,235 | 11,099 | |||
Capital expenditures (additions to property and equipment, $M)($M) | 2,933 | 2,326 | 2,547 | 2,087 | 1,697 | 1,510 | 1,496 | 1,351 | 1,225 | 986 | 1,071 | ||
Depreciation and amortization expense ($M)($M) | 534 | 509 | 586 | 470 | 478 | 463 | 485 | 467 | 414 | 401 | 387 | ||
Goodwill ($M)($M) | 8,849 | 6,130 | 5,898 | 5,898 | 5,771 | 5,771 | 5,770 | 5,768 | 5,768 | 4,940 | 4,940 | ||
Other intangible assets, net ($M)($M) | 18,110 | 7,374 | 6,521 | 6,447 | 5,908 | 6,012 | 6,166 | 6,537 | 6,636 | 6,762 | 6,907 | ||
Prepaid income taxes ($M)($M)1 | 13,600 | 11,800 | 12,900 | 18,690 | 16,400 | 7,100 | 4,260 | ||||||
Noncurrent accrued income taxes ($M)($M) | 5,461 | 5,289 | 5,875 | 6,294 | 5,684 | 5,371 | 4,061 | 3,879 | 3,497 | 4,189 | 3,849 | ||
Long-term debt, noncurrent ($M)($M)1 | 47,858 | 39,370 | 40,868 | 40,874 | 34,180 | 34,500 | 28,527 | 29,045 | 23,730 | 24,560 | 18,321 | ||
Short-term borrowings and current maturities of long-term debt ($M)($M)1 | 7,050 | 4,000 | 1,635 | 1,633 | 5,724 | 4,016 | 5,117 | 2,074 | 5,162 | 1,652 | 6,905 | ||
Commercial paper outstanding ($M)($M) | 5,284 | 1,775 | 0 | 0 | 4,092 | 2,489 | 4,338 | 1,295 | 4,385 | 985 | 6,189 | ||
FX forward contracts (not designated as hedging instruments) — Long notional ($M)($M)3 | 17,869 | 13,297 | 14,281 | 8,755 | |||||||||
FX forward contracts (not designated as hedging instruments) — Short notional ($M)($M) | 10,123 | 5,520 | 9,264 | 8,848 | |||||||||
FX forward contracts (net investment hedges) — Long notional ($M)($M) | 246 | 297 | 67 | 8,909 | |||||||||
Foreign-currency principal notes (designated as net investment hedges) — Notional ($M)($M) | 3,600 | 3,600 | 6,000 | 5,300 | |||||||||
Dividends paid per share ($)($)1 | 1.73 | 1.73 | 1.50 | 1.50 | 1.50 | 1.50 | 1.30 | 1.30 | 1.30 | 1.30 | 1.13 | ||
Cash dividends paid ($M)($M) | 1,546 | 1,548 | 1,346 | 1,346 | 1,347 | 1,346 | 1,168 | 1,171 | 1,172 | 1,169 | 1,018 | ||
Cash paid for share repurchases ($M)($M)2 | 1,601 | 2,356 | 1,508 | 708 | 692 | 1,200 | 2,054 | 446 | 0 | 0 | 0 | ||
Share repurchase program total authorization ($M)($M) | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | ||||||
Share repurchase authorization remaining ($M)($M) | 7,000 | 8,600 | 10,900 | 12,400 | 13,110 | 13,800 | 1,980 | 2,500 | 2,500 | 2,500 | |||
Stock-based compensation expense — Pretax ($M)($M) | 201 | 161 | 136 | 151 | 185 | 154 | 142 | 133 | 211 | 159 | 121 | ||
Employee Benefit Trust assets ($M)($M) | 3,013 | 3,013 | 3,013 | 3,013 | 3,013 | 3,013 | 3,000 | 3,013 | 3,013 | 3,013 | 3,010 | ||
U.S. Personal Consumption Expenditures: Health Care — SAAR ($B)(M) | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | ||
Revenue ($M)($M)13 | 22,974 | 19,799 | 19,292 | 17,601 | 15,558 | 12,729 | 13,533 | 11,439 | 11,303 | 8,768 | 9,353 | ||
Cost of sales ($M)($M) | 3,268 | 3,577 | 3,372 | 3,008 | 2,448 | 2,225 | 2,404 | 2,171 | 2,170 | 1,674 | 1,788 | ||
Research and development ($M)($M) | 3,819 | 3,510 | 3,802 | 3,466 | 3,336 | 2,734 | 3,023 | 2,734 | 2,711 | 2,523 | 2,562 | ||
Marketing, selling, and administrative ($M)($M) | 3,430 | 2,934 | 3,131 | 2,741 | 2,753 | 2,468 | 2,425 | 2,100 | 2,117 | 1,952 | 1,926 | ||
Asset impairment, restructuring, and other special charges ($M)($M) | 703 | 279 | 84.1 | 365 | 0 | 35 | 344 | 81.6 | 435 | 0 | 68 | ||
Interest income ($M) [reported separately through Q3 2025]($M) | 65 | 40 | 48.3 | 44.3 | 47.8 | 37.3 | 45.8 | 44.5 | |||||
Other — net, (income) expense ($M)($M) | 269 | -65 | -108 | -133 | -90 | -239 | -111 | 62 | -198 | 27.1 | 121 | ||
Income before income taxes ($M)($M) | 9,247 | 8,850 | 8,266 | 7,232 | 6,777 | 3,456 | 5,038 | 1,588 | 3,517 | 2,536 | 2,508 | ||
Income taxes ($M)($M) | 2,152 | 1,454 | 1,629 | 1,650 | 1,116 | 697 | 629 | 618 | 550 | 293 | 319 | ||
Net income ($M)($M) | 7,095 | 7,396 | 6,638 | 5,583 | 5,661 | 2,759 | 4,410 | 970 | 2,967 | 2,243 | 2,189 | ||
Earnings per share — Basic ($)($) | 7.95 | 8.27 | 6.22 | 6.30 | 3.07 | 1.08 | 3.29 | 2.49 | |||||
Earnings per share — Diluted ($)($) | 7.94 | 8.26 | 6.21 | 6.29 | 3.06 | 1.07 | 3.28 | 2.48 | |||||
Weighted-average shares outstanding — Basic (millions)(M) | 892 | 895 | 897 | 898 | 899 | 901 | 901 | 901 | |||||
Weighted-average shares outstanding — Diluted (millions)(M) | 894 | 896 | 899 | 900 | 901 | 905 | 904 | 904 | |||||
Total assets ($M)($M)7 | 142,283 | 116,576 | 112,476 | 114,935 | 100,923 | 89,389 | 78,715 | 75,607 | 71,875 | 63,944 | 64,006 | ||
Total current assets ($M)($M)6 | 64,672 | 54,835 | 55,629 | 62,071 | 49,854 | 41,261 | 32,740 | 31,415 | 30,204 | 25,189 | 25,727 | ||
Cash and cash equivalents ($M)($M) | 8,950 | 5,282 | 7,268 | 9,792 | 3,376 | 3,093 | 3,268 | 3,369 | 3,224 | 2,460 | 2,819 | ||
Short-term investments ($M) [through Q3 2025]($M) | 122 | 170 | 127 | 155 | 149 | 140 | 126 | 109 | |||||
Accounts receivable, net ($M)($M) | 20,083 | 18,429 | 17,760 | 16,107 | 14,170 | 12,037 | 11,006 | 10,295 | 11,028 | 7,886 | 9,091 | ||
Inventories ($M)($M) | 16,793 | 14,529 | 13,744 | 12,180 | 11,014 | 9,311 | 7,589 | 7,460 | 6,482 | 6,102 | 5,773 | ||
Prepaid expenses and other ($M)($M) | 15,368 | 13,633 | 14,315 | 20,249 | 18,020 | 14,654 | 8,341 | 8,251 | 7,138 | 6,349 | 5,541 | ||
Other current assets ($M)($M) | 86 | 214 | 147 | 272 | 68.8 | 72.4 | 266 | 135 | 142 | 139 | 150 | ||
Property and equipment, net ($M)($M) | 29,286 | 26,540 | 24,675 | 22,316 | 20,530 | 18,474 | 17,102 | 16,172 | 14,829 | 13,624 | 12,914 | ||
Goodwill ($M)($M) | 8,849 | 6,130 | 5,898 | 5,898 | 5,771 | 5,771 | 5,770 | 5,768 | 5,768 | 4,940 | 4,940 | ||
Other intangibles, net ($M)($M) | 18,110 | 7,374 | 6,521 | 6,447 | 5,908 | 6,012 | 6,166 | 6,537 | 6,636 | 6,762 | 6,907 | ||
Deferred tax assets ($M)($M) | 10,028 | 11,350 | 9,959 | 8,963 | 9,427 | 8,573 | 8,001 | 7,392 | 6,655 | 5,634 | 5,477 | ||
Sundry / long-term investments ($M)($M) | 3,856 | 3,116 | 2,802 | 2,808 | 3,207 | 3,223 | 3,216 | 3,200 | 2,878 | 3,087 | 3,052 | ||
Other noncurrent assets ($M)($M) | 7,482 | 7,231 | 6,992 | 6,432 | 6,225 | 6,075 | 5,720 | 5,122 | 4,904 | 4,708 | 4,990 | ||
Total liabilities ($M)3 | |||||||||||||
Total current liabilities ($M)($M)4 | 47,741 | 36,634 | 35,228 | 40,141 | 39,020 | 30,068 | 28,376 | 24,674 | 27,121 | 18,598 | 27,293 | ||
Short-term borrowings and current maturities of long-term debt ($M)($M) | 7,050 | 4,000 | 1,635 | 1,633 | 5,724 | 4,016 | 5,117 | 2,074 | 5,162 | 1,652 | 6,905 | ||
Accounts payable ($M)($M) | 6,112 | 5,029 | 5,379 | 4,262 | 4,076 | 3,442 | 3,229 | 2,887 | 2,925 | 2,474 | 2,599 | ||
Income taxes payable ($M) [through Q3 2025]($M) | 9,444 | 6,958 | 6,176 | 1,116 | |||||||||
Other current liabilities ($M)($M) | 11,659 | 8,699 | 8,457 | 5,215 | 5,077 | 3,770 | 6,397 | 5,580 | 4,249 | 4,199 | 3,281 | ||
Long-term debt ($M)($M) | 47,858 | 39,370 | 40,868 | 40,874 | 34,180 | 34,500 | 28,527 | 29,045 | 23,730 | 24,560 | 18,321 | ||
Other noncurrent liabilities ($M)($M) | 7,344 | 4,085 | 3,970 | 3,777 | 2,345 | 2,288 | 3,479 | 2,239 | 2,471 | 2,271 | 2,241 | ||
Total equity ($M)($M)6 | 33,879 | 31,198 | 26,535 | 23,851 | 18,349 | 15,847 | 14,272 | 14,321 | 13,636 | 12,897 | 10,864 | ||
Common stock ($M)($M) | 588 | 590 | 590 | 591 | 592 | 593 | 592 | 594 | 594 | 594 | 594 | ||
Additional paid-in capital ($M)($M) | 7,117 | 6,921 | 7,346 | 7,232 | 7,089 | 6,910 | 7,439 | 7,340 | 7,214 | 7,010 | 7,250 | ||
Retained earnings ($M)($M) | 31,893 | 29,514 | 24,470 | 22,252 | 17,376 | 15,100 | 13,545 | 13,627 | 13,178 | 12,554 | 10,312 | ||
Accumulated other comprehensive loss ($M)($M) | -2,761 | -2,833 | -2,880 | -3,206 | -3,716 | -3,775 | -4,322 | -4,275 | -4,379 | -4,300 | -4,327 | ||
Cost of common stock in treasury ($M) [through Q3 2025]($M) | -62.5 | -55.4 | -49.5 | -49.5 | -32.7 | -32.7 | -32.7 | -44.2 | |||||
Noncontrolling interests ($M) [through Q3 2025]($M) | 57.5 | 76.2 | 82 | 79.5 | 80.7 | 73.5 | 85.2 | 91.8 | |||||
Net cash provided by operating activities ($M)($M)6 | 10,690 | 5,333 | 3,225 | 8,835 | 3,087 | 1,666 | 2,474 | 3,712 | 1,466 | 1,166 | -312 | ||
Depreciation and amortization ($M)($M) | 534 | 509 | 586 | 470 | 478 | 463 | 485 | 467 | 414 | 401 | 387 | ||
Stock-based compensation expense ($M)($M) | 201 | 161 | 136 | 151 | 185 | 154 | 142 | 133 | 211 | 159 | 121 | ||
Net cash used for investing activities ($M)($M)1 | -15,396 | -3,916 | -2,802 | -2,983 | -1,834 | -3,353 | -1,921 | -4,005 | -2,199 | -1,178 | -2,925 | ||
Other investing activities, net ($M)($M) | -127 | -31 | 56.8 | -308 | 141 | 111 | -678 | 373 | 105 | -48.2 | 71.1 | ||
Net cash provided by / (used for) financing activities ($M)($M)6 | 8,426 | -3,470 | -2,879 | 531 | -1,245 | 1,380 | -226 | 211 | 1,556 | -311 | 3,545 | ||
Dividends paid to shareholders ($M)($M) | 1,546 | 1,548 | 1,346 | 1,346 | 1,347 | 1,346 | 1,168 | 1,171 | 1,172 | 1,169 | 1,018 | ||
Purchases of common stock / share repurchases ($M)($M) | 1,601 | 2,356 | 1,508 | 708 | 692 | 1,200 | 2,054 | 446 | -0 | -0 | -0 | ||
Issuances of long-term debt ($M)($M) | 8,941 | 0 | -0.20 | 6,706 | 0 | 6,461 | -0.10 | 4,965 | 0 | 6,453 | 0.50 | ||
Repayments of long-term debt ($M)($M) | 873 | 750 | -0.10 | 0.10 | 778 | -0 | -0.20 | -0 | -0 | ||||
Net change in short-term borrowings ($M)($M) | 3,509 | 1,775 | -0.40 | -4,092 | 1,603 | -1,849 | 3,042 | -3,089 | 3,400 | -5,205 | 4,594 | ||
Other financing activities, net ($M)($M) | -4 | -591 | -25.1 | -29.9 | -31 | -686 | -45.9 | -47.3 | -8 | -390 | -31.6 | ||
Effect of exchange rate changes on cash and equivalents ($M)($M) | -52 | 67 | -67.1 | 32.1 | 275 | 132 | -429 | 227 | -59.6 | -35.5 | 130 | ||
Net increase / (decrease) in cash and cash equivalents ($M)($M) | 3,668 | -1,986 | -2,524 | 6,416 | 283 | -175 | -101 | 145 | 763 | -358 | 438 | ||
97 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Eli Lilly and Company operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026).
- Core operational & financial KPIs (Groups 1–5) cover: (1) Revenue Disaggregation by Product ($60,958M in FY25) vs. Collaboration & Other ($4,221M in FY25), Geography (U.S. $43,481M vs. Outside U.S. $21,698M across Europe $11,558M, Japan $2,132M, China $1,951M & Rest of World $6,057M), and Volume / Realized Price / Foreign Exchange Revenue Growth Drivers across Worldwide, U.S., and Outside U.S. (42 periods FY17–FY26Q2; Q2 2026 WW +48% driven by +52% volume and -6% price); (2) Therapeutic Area & Medicine Revenue across Cardiometabolic Health (Mounjaro $9,943M & Zepbound $4,928M in Q2 2026; $22,965M & $13,542M in FY25, plus Trulicity, Jardiance & Other Cardiometabolic), Oncology (Verzenio $1,474M in Q2 2026; $5,723M in FY25), Immunology (Taltz), Neuroscience, and 18 legacy/established medicines & historical Elanco Animal Health segment; (3) U.S. Gross-to-Net (GTN) Rebates, Discounts & Returns Liability ($21,122M at Q2 2026; 96% U.S.) and full 10-year U.S. GTN Rollforward ($54,757M GTN provision and $48,885M cash rebate payments in FY25), and U.S. Portfolio List (+2.9%) vs. Net Price Realized (39% of list in FY25); (4) R&D Pipeline Expense Split between Early-Stage Research/Discovery ($4,881M in FY25) and Late-Stage Clinical Development ($8,456M in FY25), Acquired IPR&D charges ($2,910M in FY25), Advertising ($2,900M / 5.0% of revenue in FY25), and Restructuring/Impairment; and (5) GAAP vs. Non-GAAP Gross Margin (84.8% GAAP / 85.4% Non-GAAP in Q2 2026), Non-GAAP Net Income & Diluted EPS ($8.41 in Q2 2026; $24.21 in FY25), GAAP vs. Non-GAAP Effective Tax Rates, Current & Deferred Federal/Foreign Taxes, Deferred Tax Assets by attribute, and Unrecognized Tax Benefits ($5,082M at FY25).
- Groups 6–9 cover Manufacturing, Inventory, PP&E, Intangibles & Leases (LIFO/FIFO Inventories $16,793M net at Q2 2026 including $9,997M WIP, $1,500M pre-launch capitalized inventory, Gross PP&E $37,235M at FY25 including $13,013M Construction in Progress, Geographic Long-Lived Assets across U.S. $18,764M & Ireland $4,321M, Goodwill $8,849M, Other Intangibles $18,110M net with 5-year amortization schedule, and Operating Leases), Debt, Derivatives & Capital Return ($47,858M long-term debt & $5,284M commercial paper at Q2 2026, $17,869M long / $10,123M short FX forward contracts, Dividends, Share Repurchases, SBC & Employee Benefit Trust), Workforce, Compensation, Form 11-K 401(k) & Defined Benefit Pensions (50,000 employees, 23,000 outside U.S., 12,000 in R&D, 9% turnover, 85 training hours, CEO pay ratio 293:1, $15.62B Lilly 401(k) Plan & $634.8M Puerto Rico Savings Plan, and $14.26B Pension PBO / $14.82B Plan Assets across 6 asset classes), and Lilly 30x30 Global Health Reach (40M people in FY25) & Environmental/Safety KPIs (79.3% renewable electricity, 96.8% water recycle rate, Scope 1/2/3 GHG emissions).
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'between 16% and 24% wholesaler revenue concentration' and 'less than 1% product returns / prior-period GTN adjustments' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-10-25.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Revenue Disaggregation & Volume / Price / FX Growth Drivers
Therapeutic Area & Medicine Revenue (Key Products & Legacy Portfolio)
- Cardiometabolic Health — U.S. revenue ($M) ($M)13 kỳ
- Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M) ($M)19 kỳ
- Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M) ($M)14 kỳ
- Trulicity (dulaglutide) — U.S. revenue ($M) ($M)38 kỳ
- Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M) ($M)38 kỳ
- Other Cardiometabolic Health medicines — U.S. revenue ($M) ($M)13 kỳ
- Oncology — U.S. revenue ($M) ($M)38 kỳ
- Verzenio (abemaciclib) — Worldwide revenue ($M) ($M)34 kỳ
- Other Oncology medicines — U.S. revenue ($M) ($M)38 kỳ
- Immunology — U.S. revenue ($M) ($M)38 kỳ
- Taltz (ixekizumab) — U.S. revenue ($M) ($M)38 kỳ
- Other Immunology medicines — U.S. revenue ($M) ($M)38 kỳ
- Neuroscience — U.S. revenue ($M) ($M)38 kỳ
- Other therapeutic areas — U.S. revenue ($M) ($M)38 kỳ
- Non-major products combined ('Other products' in MD&A) — Worldwide revenue ($M) [Q1–Q3 10-Q & FY 10-K] ($M)38 kỳ
- Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure] ($M)32 kỳ
- Humulin (human insulin) — Worldwide revenue ($M) [legacy separate disclosure] ($M)32 kỳ
- Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)32 kỳ
- Cyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)32 kỳ
- Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)55 kỳ
- Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)27 kỳ
- Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure] ($M)28 kỳ
- Tyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)22 kỳ
- Alimta (pemetrexed) — Worldwide revenue ($M) [legacy separate disclosure] ($M)28 kỳ
- Forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure] ($M)31 kỳ
- Cialis (tadalafil) — Worldwide revenue ($M) [legacy separate disclosure] ($M)31 kỳ
- Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)28 kỳ
- Cymbalta (duloxetine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)24 kỳ
- Strattera (atomoxetine) — Worldwide revenue ($M) [legacy separate disclosure] ($M)12 kỳ
- Effient (prasugrel) — Worldwide revenue ($M) [legacy separate disclosure] ($M)28 kỳ
- Trajenta (linagliptin) — Worldwide revenue ($M) [legacy separate disclosure] ($M)33 kỳ
- Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure] ($M)12 kỳ
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)16 kỳ
- Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy] (%)7 kỳ
- Diabetes therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2023] ($M)15 kỳ
- Endocrinology therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2019] ($M)24 kỳ
- Cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M)21 kỳ
- Elanco Animal Health segment — Revenue ($M) [legacy segment spun off March 2019] ($M)23 kỳ
Gross-to-Net (GTN) Rebates, Discounts & U.S. Pricing
R&D Pipeline Stage Breakdown, IPR&D & Commercial Expenses
GAAP vs. Non-GAAP Profitability & Income Tax Footnotes
- GAAP gross margin ($M) ($M)33 kỳ
- Non-GAAP gross margin ($M) ($M)18 kỳ
- Non-GAAP net income ($M) ($M)37 kỳ
- GAAP effective tax rate (%) (%)30 kỳ
- Current income tax expense — Total ($M) ($M)10 kỳ
- Deferred income tax expense / (benefit) — Total ($M) ($M)10 kỳ
- Cash paid for income taxes, net ($M) ($M)3 kỳ
- Net deferred tax asset / (liability) ($M) ($M)9 kỳ
- Unrecognized tax benefits (UTB) — Ending balance ($M) ($M)10 kỳ
Manufacturing, Inventory, PP&E, Intangibles & Lease Footnotes
- Total inventories, net ($M) ($M)42 kỳ
- Property and equipment, net ($M) ($M)42 kỳ
- Geographic long-lived assets — Consolidated total ($M) ($M)10 kỳ
- Capital expenditures (additions to property and equipment, $M) ($M)27 kỳ
- Depreciation and amortization expense ($M) ($M)68 kỳ
- Goodwill ($M) ($M)42 kỳ
- Other intangible assets, net ($M) ($M)42 kỳ
- Operating lease right-of-use (ROU) assets ($M) ($M)5 kỳ
- Prepaid income taxes ($M) ($M)10 kỳ
Debt, Derivatives, Share Repurchases & Stock-Based Compensation
- Long-term debt, noncurrent ($M) ($M)42 kỳ
- FX forward contracts (not designated as hedging instruments) — Long notional ($M) ($M)4 kỳ
- Dividends paid per share ($) ($)61 kỳ
- Cash paid for share repurchases ($M) ($M)56 kỳ
- Stock-based compensation expense — Pretax ($M) ($M)68 kỳ
- Employee Benefit Trust assets ($M) ($M)42 kỳ
Workforce, Compensation, 401(k) Plans (Form 11-K) & Defined Benefit Pensions
- Total global employees9 kỳ
- CEO to median employee pay ratio (x) (×)7 kỳ
- Lilly Employee 401(k) Plan — Net assets available for benefits ($) ($)9 kỳ
- Defined benefit pension plans — Projected benefit obligation (PBO, $M) ($M)10 kỳ
- Retiree health benefit plans — Accumulated postretirement benefit obligation (APBO, $M) ($M)10 kỳ
Global Health Access, Environmental & Safety KPIs
- Lilly 30x30 Global Health — People reached annually in resource-limited settings (millions) (M)5 kỳ
- Scope 1 direct GHG emissions (metric tonnes CO2e)7 kỳ
- Renewable electricity share of purchased electricity (%) (%)6 kỳ
- Water recycle and reuse rate (%) (%)7 kỳ
- Routine operational waste sent to landfill (% of routine waste) (%)4 kỳ
- Workforce severe injury rate (per 500 employees) (×)6 kỳ
Industry & Macroeconomic Benchmarks (BEA, Census & BLS via FRED)
Consolidated Financial Statements (Postgres DB)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Eli Lilly
- Form 10-Q (filed 2026-08-05) ↗
- Form 10-K (filed 2026-02-12) ↗
- Form 10-K FY2024 (filed 2025-02-19) ↗
- Form 10-K FY2025 (filed 2026-02-12) ↗
- Form 10-K (filed 2025-02-19) ↗
- Lilly 2025 Sustainability Highlights Report ↗
- Form 10-Q FY2026Q2 (filed 2026-08-05) ↗
- Earnings Release (Form 8-K FY2026Q2 EX-99.1) (filed 2026-08-05) ↗
- Earnings Release (Form 8-K FY2025Q4 EX-99.1) (filed 2026-02-04) ↗
- Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗
- Form 10-K FY2023 (filed 2024-02-21) ↗
- Form 10-Q (filed 2024-10-30) ↗
See a number that looks wrong?